This new capital will be invested by Menlo XVI, Menlo Inflection III, and their affiliated funds, in promising technology companies leading the AI transformation.
We surveyed more than 450 enterprise executives across the U.S. and Europe and spoke to a dozen more to provide a view into generative AI adoption in the enterprise today.
Building a business is a team sport. As investors, we don’t just sit on the sidelines but do whatever it takes to help our teams win.
The founders we back don’t limit themselves to what is, but relentlessly pursue what could be. We invest in transformative technology companies that are changing the way we live and work.
Menlo Labs starts companies. We work shoulder-to-shoulder alongside visionary founders to help groundbreaking ideas break ground.
When we’re in, we’re ALL IN. From our partners to our Fuel team, we are deeply committed to our companies as they navigate every stage of growth.
We’re thrilled to lead OfferFit’s Series B and believe it delivers a category-disrupting solution at a time when the marketing world is looking to embrace AI.
Developers have become increasingly powerful decision makers and influencers within organizations, with purchasing powers of their own and dedicated budgets—particularly in light of the explosive growth of GenAI.
Predictive and generative AI are entering many new applications. At Menlo Ventures, we are especially excited about applications for AI in drug discovery and development, specifically when new technology can directly address a major unmet need.
Founder Devin Bhushan talks about Squint and making the leap to entrepreneurship with the help of Menlo Labs.